Drugs / iNK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06245018 | Feb 2024 → Mar 2027 expected | neoplasm | Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06245018 ↗ |
| Modality | Cell therapy | “Human Induced Pluripotent Stem Cell Derived Natural Killer Cells (iNK)” NCT06245018 ↗ |